A GLOBAL, PHASE 1/2, OPEN-LABEL, DOSE OPTIMIZATION STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF MRNA-3927 IN PARTICIPANTS WITH PROPIONIC ACIDEMIA

Registry ID

MRNA-3927-P101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

MODERNATX, INC.

Start date

2021-04-07

Last update

2020-12-02

Conditions

• PROPIONIC ACIDEMIA

Related clinical trials

• A PHASE 1/2, GLOBAL, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND CLINICAL ACTIVITY OF MRNA-3927 IN PARTICIPANTS PREVIOUSLY ENROLLED IN THE MRNA-3927-P101 STUDY

View on source registry